IDH3A and myeloid neoplasm: In addition, isocitrate dehydrogenase (IDH) and bromodomain and extraterminal (BET) inhibitors have also been reported in the treatment of myeloid neoplasms (107, 108), and further studies should be carried out to elucidate the role of IDH and BET inhibitors in the HSCT setting.